- Home
- HYPR vs VRCA Comparison
HYPR vs VRCA Comparison
Compare HYPR & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYPR
- VRCA
- Stock Information
- Founded
- HYPR 2014
- VRCA 2013
- Country
- HYPR United States
- VRCA United States
- Employees
- HYPR N/A
- VRCA N/A
- Industry
- HYPR Medical Specialities
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- HYPR Health Care
- VRCA Health Care
- Exchange
- HYPR Nasdaq
- VRCA Nasdaq
- Market Cap
- HYPR 54.6M
- VRCA 58.0M
- IPO Year
- HYPR N/A
- VRCA 2018
- Fundamental
- Price
- HYPR $0.74
- VRCA $0.44
- Analyst Decision
- HYPR Strong Buy
- VRCA Hold
- Analyst Count
- HYPR 3
- VRCA 5
- Target Price
- HYPR $1.33
- VRCA $6.00
- AVG Volume (30 Days)
- HYPR 2.7M
- VRCA 543.9K
- Earning Date
- HYPR 03-17-2025
- VRCA 05-12-2025
- Dividend Yield
- HYPR N/A
- VRCA N/A
- EPS Growth
- HYPR N/A
- VRCA N/A
- EPS
- HYPR N/A
- VRCA N/A
- Revenue
- HYPR $12,890,000.00
- VRCA $7,566,000.00
- Revenue This Year
- HYPR $24.00
- VRCA $118.94
- Revenue Next Year
- HYPR $28.70
- VRCA $94.35
- P/E Ratio
- HYPR N/A
- VRCA N/A
- Revenue Growth
- HYPR 16.84
- VRCA 47.66
- 52 Week Low
- HYPR $0.68
- VRCA $0.39
- 52 Week High
- HYPR $1.90
- VRCA $11.41
- Technical
- Relative Strength Index (RSI)
- HYPR 39.35
- VRCA 32.87
- Support Level
- HYPR $0.68
- VRCA $0.39
- Resistance Level
- HYPR $0.96
- VRCA $0.66
- Average True Range (ATR)
- HYPR 0.08
- VRCA 0.07
- MACD
- HYPR -0.01
- VRCA -0.01
- Stochastic Oscillator
- HYPR 8.09
- VRCA 17.82
About HYPR Hyperfine Inc.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.